Research Article
Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases
Table 8
Theoretical and observed drug load and encapsulation efficiency of buparvaquone nanostructured lipid carriers.
| | | BPQ theoretical concentration (μg·mL−1) () | Total observed BPQ concentration (μg·mL−1) | Supernatant BPQ (μg·mL−1) | Encapsulation efficiency (%) |
| | F1 | 320 | 312.5 ± 1.4 | 0.13 ± 0.02 | 99.96 ± 0.06% | | F3 | 400 | 403.57 ± 5.0 | <limit of detection | 100.00% | | F4 | 500 | 477.87 ± 1.9 | 0.06 ± 0.01 | 99.99 ± 0.02% |
|
|
